BCIQ Profiles

Company Profile ReportTarget Profile Report

Auris reports additional Phase III data of brimapitide for hearing loss

Auris Medical Holding AG (NASDAQ:EARS) reported additional data from the Phase III HEALOS trial evaluating single intratympanic doses of 0.4 and 0.8 mg/mL brimapitide (AM-111, D-JNKI-1, XG-102) gel in 256

Read the full 302 word article

How to gain access

Continue reading with a
two-week free trial.